Investor Presentaiton

For personal use only • IPAX-I Phase I/II trial of TLX101 for the treatment of GBM 1 TLX101 in combination with EBRT2 • Multi-centre Phase I/II trial of TLX101 in combination with EBRT in patients with recurrent GBM . Primary endpoint: Safety and tolerability Secondary endpoints include: MTD³, efficacy, dosimetry First-peer review data presented at Congress of Neurological Surgeons (CNS) Annual Meeting in October 2021 . All patients evaluated received similar total activity dose of ~2GBq (2000 MBq) of TLX101, either in a single administration or a triple-fractionated regime. • Treatment well tolerated, typically grade 1 - 2 adverse events Evidence of anti-tumour effect from both imaging and clinical assessment • Overall survival (OS) on this interim analysis shows median 15.97 months to date 6/10 patients still alive and will be followed until 1 year after dosing for the final OS calculation (May 2022) 1. Glioblastoma Multiforme. 2. External beam radiation therapy 3. Maximum tolerated dose. Telix Pharmaceuticals Limited (ASX: TLX) Baseline PET scan Day 45 PET scan post TLX101 therapy TELIX PHARMACEUTICALS 47

View entire presentation